Skip to the page

Data / Form D filings / Gaius Therapeutics, Inc,

Gaius Therapeutics, Inc,: Form D filing

Gaius Therapeutics, Inc,, a biotechnology company in San Diego, CA, filed a Form D with the SEC in 2026. The latest, on May 14, 2026, reports $60,000 sold of a $250,000 offering to 2 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
9276 SCRANTON ROAD, SUITE 500, San Diego, CA, 92121
Phone
(650) 255-8226
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2026
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2132841

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
May 14, 2026New notice$250,000$60,000$190,0002May 7, 2026sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Jesse Joseph SolvasonExecutive Officer, Director
Adam KlieExecutive Officer
Javid AceilExecutive Officer
Ben WangDirector
Christopher EmigDirector
Michon PinnixDirector

Other biotechnology companies in California that filed recently

Every Form D from the week of May 11, 2026 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Gaius Therapeutics, Inc, reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.